PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Mexiletine hydrochloride - Arrhythmias

PAD Profile : Mexiletine hydrochloride - Arrhythmias

Keywords :
drug resistant ventricular arrhythmias, sodium channel blockers, ventricular tachycardia
Brand Names Include :
Namuscla

Traffic Light Status

Status 1 of 1.

Status :
Red
Important
Formulations :
  • Capsules
Important Information :
Namuscla brand is non-preferred for this indication
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
05 June 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee approves the prescribing of mexiletine for the management of drug resistant ventricular arrhythmia when initiated and continued by a specialist.

The APC recommend a RED traffic light status for the use of mexiletine for this indication.

All patients currently being prescribed mexiletine in primary care should be referred into a cardiologist for specialist review. Responsibility for prescribing must remain with the specialist.

Patients currently prescribed Namuscla® for the management of drug resistant arrhythmias should be reviewed by specialists to consider switching to the products licensed for ventricular arrhythmias noting that there isn’t an exact equivalent dose. 

Associated BNF Codes

02. Cardiovascular System
02.03.02. Drugs for arrhythmias
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More